334 related articles for article (PubMed ID: 37920162)
1. Checkpoint inhibition in hematologic malignancies.
Tsumura A; Levis D; Tuscano JM
Front Oncol; 2023; 13():1288172. PubMed ID: 37920162
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers for checkpoint inhibition in hematologic malignancies.
Atanackovic D; Luetkens T
Semin Cancer Biol; 2018 Oct; 52(Pt 2):198-206. PubMed ID: 29775689
[TBL] [Abstract][Full Text] [Related]
3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
4. Programming the immune checkpoint to treat hematologic malignancies.
Vick E; Mahadevan D
Expert Opin Investig Drugs; 2016 Jul; 25(7):755-70. PubMed ID: 27070269
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of immune checkpoint based approaches in AML and MDS.
Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint inhibition in pediatric hematologic malignancies.
Davis KL; Agarwal AM; Verma AR
Pediatr Hematol Oncol; 2017; 34(6-7):379-394. PubMed ID: 29190182
[TBL] [Abstract][Full Text] [Related]
7. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
8. Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors?
Jeong AR; Ball ED; Goodman AM
Clin Med Insights Oncol; 2020; 14():1179554920976366. PubMed ID: 33447123
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint blockade in hematological malignancies: current state and future potential.
Pophali P; Varela JC; Rosenblatt J
Front Oncol; 2024; 14():1323914. PubMed ID: 38322418
[TBL] [Abstract][Full Text] [Related]
10. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
Kreidieh FY; Tawbi HA
Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
[TBL] [Abstract][Full Text] [Related]
11. Immune-Checkpoint Blockade Therapy in Lymphoma.
Kuzume A; Chi S; Yamauchi N; Minami Y
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751706
[TBL] [Abstract][Full Text] [Related]
12. Targeting Immune Checkpoints in Hematologic Malignancies.
Alatrash G; Daver N; Mittendorf EA
Pharmacol Rev; 2016 Oct; 68(4):1014-1025. PubMed ID: 27664133
[TBL] [Abstract][Full Text] [Related]
13. Current studies of immunotherapy in head and neck cancer.
Dogan V; Rieckmann T; Münscher A; Busch CJ
Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies.
Chao MP; Takimoto CH; Feng DD; McKenna K; Gip P; Liu J; Volkmer JP; Weissman IL; Majeti R
Front Oncol; 2019; 9():1380. PubMed ID: 32038992
[TBL] [Abstract][Full Text] [Related]
15. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy.
Bryan LJ; Gordon LI
Blood Rev; 2015 Jan; 29(1):25-32. PubMed ID: 25260226
[TBL] [Abstract][Full Text] [Related]
16. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint blockade for hematologic malignancies: a review.
Pianko MJ; Liu Y; Bagchi S; Lesokhin AM
Stem Cell Investig; 2017; 4():32. PubMed ID: 28529947
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe?
Davoodi-Moghaddam Z; Jafari-Raddani F; Noori M; Bashash D
Transl Oncol; 2023 Apr; 30():101636. PubMed ID: 36773442
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
20. New Clinical Approaches and Emerging Evidence on Immune-Checkpoint Inhibitors as Anti-Cancer Therapeutics: CTLA-4 and PD-1 Pathways and Beyond.
Christodoulou MI; Zaravinos A
Crit Rev Immunol; 2019; 39(5):379-408. PubMed ID: 32422018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
